Yes, cabotegravir injection and hepatitis B vaccination can be administered on the same day
Cabotegravir injection and hepatitis B vaccine can be safely co-administered on the same day at separate anatomical injection sites (e.g., separate limbs). This is explicitly supported by both FDA labeling and CDC guidelines.
Evidence Supporting Same-Day Administration
The FDA prescribing information for cabotegravir clearly states that "HepB vaccine may be administered simultaneously with HBIG at a separate anatomical injection site (e.g., separate limbs)" 1. While this specific guidance addresses post-exposure prophylaxis scenarios, the principle of separate-site administration applies broadly to vaccine co-administration.
CDC guidelines consistently emphasize that hepatitis B vaccine "can be administered with other vaccines" when given intramuscularly in the deltoid muscle 2. The 2018 ACIP recommendations reinforce that "vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events" 1.
Practical Administration Guidelines
Injection Site Selection
- Administer cabotegravir via gluteal injection (600 mg/3 mL for PrEP) 3
- Administer hepatitis B vaccine in the deltoid muscle 2
- These anatomically distinct sites eliminate any concern about local interference
Timing Considerations
For individuals initiating cabotegravir PrEP:
- Hepatitis B vaccination should ideally be completed or initiated before starting cabotegravir 3
- If not previously vaccinated, the first HepB dose can be given the same day as the first cabotegravir injection
- Continue the HepB vaccine series on schedule (0,1, and 6 months) 4
Critical Safety Caveat: Hepatitis B Screening Required
Before initiating cabotegravir (whether for HIV treatment or PrEP), hepatitis B screening is mandatory because cabotegravir lacks anti-HBV activity 5, 6, 7, 8. Recent case reports document acute hepatitis B infections and reactivations in patients on cabotegravir therapy, even among those with documented prior vaccination 5, 6, 7.
Required Pre-Treatment Assessment
- Test for HBsAg, anti-HBs, and anti-HBc 1
- Chronic HBV infection (HBsAg-positive) is a contraindication to cabotegravir monotherapy or cabotegravir/rilpivirine combination 8
- Individuals with isolated anti-HBc (past exposure without immunity) require careful monitoring 9, 8
Vaccination Strategy
- Non-immune individuals (anti-HBs negative) should receive hepatitis B vaccine 1, 3
- The first dose can be administered on the same day as cabotegravir initiation
- Post-vaccination serologic testing (anti-HBs) is recommended 1-2 months after completing the 3-dose series for high-risk populations 1
Common Pitfalls to Avoid
Do not assume prior vaccination equals immunity: Vaccine-induced antibodies wane over time, and breakthrough infections have been documented 5, 6, 7
Do not skip hepatitis B screening: Even with documented vaccination history, verify serologic immunity before starting cabotegravir 8
Do not use the same injection site: Always use separate anatomical locations (gluteal for cabotegravir, deltoid for HepB vaccine) 1
Monitor liver function tests: Routine LFT monitoring is essential during cabotegravir therapy to detect potential HBV reactivation or incident infection 10, 8
The 2025 real-world safety data from Japan confirms that when proper screening and monitoring protocols are followed, cabotegravir therapy demonstrates an acceptable safety profile 10. However, the multiple case reports of hepatitis B complications underscore the absolute necessity of comprehensive HBV assessment and vaccination before initiating therapy 5, 6, 7, 8.